Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
PLA2G6 (human)
p Phosphorylation
a Acetylation
m Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
u Ubiquitination
s Sumoylation
n Neddylation
gl O-GlcNAc
ga O-GalNAc
h Palmitoylation
ad Adenylylation
sn S-Nitrosylation
ca Caspase cleavage

Overview
PLA2G6 Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F- actin polymerization at the pseudopods. Defects in PLA2G6 are the cause of neurodegeneration with brain iron accumulation type 2B (NBIA2B). A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive extrapyramidal dysfunction leading to rigidity, dystonia, dysarthria and sensorimotor impairment. Defects in PLA2G6 are the cause of neurodegeneration with brain iron accumulation type 2A (NBIA2A); also known as Seitelberger disease. NBIA2A is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years. Defects in PLA2G6 are the cause of Parkinson disease type 14 (PARK14). An adult-onset progressive neurodegenerative disorder characterized by parkinsonism, dystonia, severe cognitive decline, cerebral and cerebellar atrophy and absent iron in the basal ganglia on magnetic resonance imaging. 4 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: Lipid Metabolism - linoleic acid; EC 3.1.1.4; Lipid Metabolism - alpha-linolenic acid; Phospholipase; Lipid Metabolism - ether lipid; Lipid Metabolism - arachidonic acid; Lipid Metabolism - glycerophospholipid
Cellular Component: mitochondrion; membrane; cytosol
Molecular Function: phospholipase A2 activity; calmodulin binding; ATP-dependent protein binding; calcium-independent phospholipase A2 activity
Biological Process: cell death; urinary bladder smooth muscle contraction; cardiolipin biosynthetic process; maternal process involved in pregnancy; glycerophospholipid biosynthetic process; negative regulation of synaptic transmission, glutamatergic; chemotaxis; positive regulation of vasodilation; memory; elevation of cytosolic calcium ion concentration; phospholipid metabolic process; innate immune response; positive regulation of protein amino acid phosphorylation; lipid catabolic process; positive regulation of exocytosis
Reference #:  O60733 (UniProtKB)
Alt. Names/Synonyms: 85 kDa calcium-independent phospholipase A2; CaI-PLA2; calcium-independent phospholipase A2; cytosolic, calcium-independent phospholipase A2; Group VI phospholipase A2; GVI; GVI PLA2; INAD1; IPLA2; IPLA2-VIA; NBIA2A; NBIA2B; PA2G6; PARK14; patatin-like phospholipase domain containing 9; phospholipase A2, group VI (cytosolic, calcium-independent); PLA2; PLA2G6; PNPLA9
Gene Symbols: PLA2G6
Molecular weight: 89,903 Da
Basal Isoelectric point: 6.86  Predict pI for various phosphorylation states
Select Structure to View Below

PLA2G6

Protein Structure Not Found.


STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  ENZYME  |  DISEASE  |  Source  |  InnateDB  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  Ensembl Gene


Modification Sites and Domains Show Modification Legend
Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 2 G13 RLVNTFSGVTNLFSN
0 1 R395 FLASKIGRLVTRKAI
0 4 Y541-p MAYMRGMyFRMKDEV
0 1 T587 PKVMLTGTLSDRQPA
1 1 Y671 AMTEIHEYNQDLIRK
0 1 T704 RSPQVPVTCVDVFRP
0 1 K725 AKTVFGAKELGKMVV
  mouse

► Hide Isoforms
 
S13-p RLVNTLSsVTNLFSN
K395 LIASKISKLITRKAL
Y542 MAYMRGVYFRMKDEV
T588-p PKVMLTGtLSDRQPA
Y672 AMTEIHEYNQDMIRK
T705-gl KSPQVPVtCVDVFRP
K726-u AKTVFGAkELGKMVV
  PLA2G6 iso2  
S13 RLVNTLSSVTNLFSN
K395-u LIASKISkQLQDLMP
Y487 MAYMRGVYFRMKDEV
T533 PKVMLTGTLSDRQPA
Y617 AMTEIHEYNQDMIRK
T650 KSPQVPVTCVDVFRP
K671 AKTVFGAKELGKMVV
  rat

 
S13 RLVNTLSSVTNLFSN
K395 FIASKISKLITRKAL
Y542-p MAYMRGVyFRMKDEV
T588 PKVMLTGTLSDRQPA
Y672-p AMTEIHEyNQDMIRK
T705 KSPQVPVTCVDVFRP
K726 AKTVFGAKELGKMVV
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.